S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$285.94
-4.14 (-1.43%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$284.38
$290.08
50-Day Range
$270.81
$306.72
52-Week Range
$187.16
$311.88
Volume
618,633 shs
Average Volume
1.22 million shs
Market Capitalization
$41.18 billion
P/E Ratio
14.56
Dividend Yield
N/A
Price Target
$309.14

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
8.1% Upside
$309.14 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.49mentions of Biogen in the last 14 days
Based on 54 Articles This Week
Insider Trading
Selling Shares
$1.68 M Sold Last Quarter
Proj. Earnings Growth
-7.78%
From $17.10 to $15.77 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

474th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

76th out of 170 stocks


BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

Cassava Sciences Stock Undervalued with Its $124 Price Target? (BIIB)
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Where Biogen Stands With Analysts
Biogen's (BIIB) "Buy" Rating Reaffirmed at Needham & Company LLC
Biogen (NASDAQ:BIIB) PT Raised to $345.00 at Morgan Stanley
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
10/19/2021
Today
1/31/2023
Next Earnings (Confirmed)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
9,610
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$309.14
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$217.00
Forecasted Upside/Downside
+8.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
28 Analysts

Profitability

Net Income
$1.56 billion
Pretax Margin
32.74%

Debt

Sales & Book Value

Annual Sales
$10.36 billion
Cash Flow
$26.80 per share
Book Value
$74.61 per share

Miscellaneous

Free Float
143,065,000
Market Cap
$41.18 billion
Optionable
Optionable
Beta
0.23

Social Links


Key Executives

  • Mr. Michael R. McDonnell CPA (Age 59)
    Exec. VP & CFO
    Comp: $1.86M
  • Ms. Susan H. Alexander Esq. (Age 66)
    Exec. VP, Chief Legal Officer & Sec.
    Comp: $1.79M
  • Mr. Christopher A. Viehbacher (Age 63)
    Pres, CEO & Director
  • Ms. Robin C. Kramer (Age 57)
    Sr. VP & Chief Accounting Officer
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Mr. Michael Hencke
    Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory (Age 55)
    Exec. VP & Chief HR Officer
  • Dr. Anabella Villalobos Ph.D. (Age 64)
    Head of Biotherapeutics & Medicinal Sciences
  • Dr. Sanjay Jariwala
    Sr. VP of Worldwide Medical













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 8 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

28 brokers have issued 12 month price objectives for Biogen's stock. Their BIIB share price forecasts range from $217.00 to $370.00. On average, they anticipate the company's share price to reach $309.14 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 on January 1st, 2023. Since then, BIIB stock has increased by 3.3% and is now trading at $285.94.
View the best growth stocks for 2023 here
.

Are investors shorting Biogen?

Biogen saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,890,000 shares, an increase of 10.5% from the December 31st total of 1,710,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the short-interest ratio is presently 1.5 days. Approximately 1.3% of the company's shares are short sold.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our BIIB earnings forecast
.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, February 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, October, 19th. The biotechnology company reported $4.77 EPS for the quarter, topping the consensus estimate of $4.09 by $0.68. The biotechnology company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.67 billion. Biogen had a trailing twelve-month return on equity of 21.31% and a net margin of 27.64%. The business's quarterly revenue was down 17.7% compared to the same quarter last year. During the same period last year, the business earned $8.84 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2022 earnings guidance on Tuesday, November, 1st. The company provided earnings per share guidance of $16.50-$17.15 for the period, compared to the consensus EPS estimate of $16.49. The company issued revenue guidance of $10.00 billion-$10.15 billion, compared to the consensus revenue estimate of $10.00 billion.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.37%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), Parnassus Investments LLC (0.21%), New York State Teachers Retirement System (0.11%), Strs Ohio (0.09%) and Wedge Capital Management L L P NC (0.09%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Stephen A Sherwin and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $285.94.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $41.18 billion and generates $10.36 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $19.64 on an earnings per share basis.

How many employees does Biogen have?

The company employs 9,610 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 1/31/2023 by MarketBeat.com Staff